Literature DB >> 25456569

2-weekly docetaxel: issues for clinical practice.

F Massari1, F Maines, E Bria, E Galligioni, O Caffo, G Tortora.   

Abstract

In the phase III trial comparing 2 docetaxel schedules (3-weekly versus 2-weekly) as first-line chemotherapy for CRPC, recently published in The Lancet Oncology, fewer serious adverse events, particularly hematologic toxicities, and longer times on treatment, in favor of the 2-weekly regimen are reported. (1,2,3.)

Entities:  

Keywords:  3-weekly schedule; doxetaxel; mCRPC

Mesh：

Substances：

Year:  2015        PMID： 25456569      PMCID： PMC4623264          DOI： 10.4161/15384047.2014.987534

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


  8 in total

1.  Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors.

Authors:  Orazio Caffo; Giovanni Pappagallo; Sonia Brugnara; Alessia Caldara; Maria Chiara di Pasquale; Antonella Ferro; Michela Frisinghelli; Viviana Murgia; Lucianna Maria Russo; Barbara Soini; Francesco Valduga; Antonello Veccia; Enzo Galligioni
Journal:  Urology       Date:  2012-03       Impact factor: 2.649

2.  Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer.

Authors:  Giuseppe Di Lorenzo; Carlo Buonerba; Adriana Faiella; Pasquale Rescigno; Mimma Rizzo; Riccardo Autorino; Sisto Perdonà; Nando Riccardi; Sarah Scagliorini; Florinda Scognamiglio; Daniele Masala; Matteo Ferro; Giovannella Palmieri; Michele Aieta; Alfredo Marinelli; Vincenzo Altieri; Sabino De Placido; Giacomo Cartenì
Journal:  BJU Int       Date:  2011-01       Impact factor: 5.588

3.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

4.  Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer.

Authors:  Petteri Hervonen; Heikki Joensuu; Timo Joensuu; Claes Ginman; Ginman Claes; Ray McDermott; McDermott Ray; Ulrika Harmenberg; Harmenberg Ulrika; Paul Nyandoto; Nyandoto Paul; Tiina Luukkaala; Luukkaala Tiina; Akseli Hemminki; Hemminki Akseli; Igor Zaitsev; Zaitsev Igor; Mirja Heikkinen; Heikkinen Mirja; Sten Nilsson; Nilsson Sten; Marjaana Luukkaa; Luukkaa Marjaanai; Ilari Lehtinen; Lehtinen Ilari; Pirkko-Liisa Kellokumpu-Lehtinen; Kellokumpu-Lehtinen Pirkko-Liisa
Journal:  Anticancer Res       Date:  2012-03       Impact factor: 2.480

5.  2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.

Authors:  Pirkko-Liisa Kellokumpu-Lehtinen; Ulrika Harmenberg; Timo Joensuu; Ray McDermott; Petteri Hervonen; Claes Ginman; Marjaana Luukkaa; Paul Nyandoto; Akseli Hemminki; Sten Nilsson; John McCaffrey; Raija Asola; Taina Turpeenniemi-Hujanen; Fredrik Laestadius; Tiina Tasmuth; Katinka Sandberg; Maccon Keane; Ilari Lehtinen; Tiina Luukkaala; Heikki Joensuu
Journal:  Lancet Oncol       Date:  2013-01-04       Impact factor: 41.316

6.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

7.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.